Aclaris Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Neal S. Walker
- Full Time Employees
- 71
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 640 Lee Road Wayne PA United States of America 19087
- IPO Date
- Oct 6, 2015
- CIK
- 0001557746
- Website
- aclaristx.com
- Similar Companies
- Business
- Aclaris Therapeutics, Inc. (Nasdaq: ACRS) is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated inflammatory diseases and cancers. The company offers a pipeline of novel drug candidates, including ATX-104, a topical JAK1 inhibitor in Phase 2 trials for alopecia areata; zunsemetinib (formerly ATI-2138), an oral MK2 inhibitor in Phase 2 for atopic dermatitis, hidradenitis suppurativa, and rheumatoid arthritis; and ATX-032, an inhaled JAK1 inhibitor for moderate-to-severe asthma; as well as earlier-stage assets like ATX-1403 (S1P1/3 modulator) and ATX-2441 (BTLA agonist antibody). These therapies target dermatological, respiratory, and oncology indications through proprietary platforms emphasizing precision immunology and targeted modulation. Founded in 2012 and headquartered in Malvern, Pennsylvania, Aclaris operates primarily in the United States with a focus on advancing its immunology and oncology portfolios for patients underserved by existing therapies.[web:previous] In the past two years, Aclaris has undergone significant strategic shifts, including the spin-off of its contract research organization business into a separate entity, FocusCRO, in October 2023 to streamline operations and concentrate resources on its drug pipeline; a corporate reorganization in 2024 that reduced headcount and costs amid pipeline prioritization; and the appointment of new leadership, such as CEO Neal Fowler in early 2024, to drive clinical execution.[web:previous] The company secured $90 million in financing through a registered direct offering in June 2024 to fund ongoing Phase 2 trials, and recently advanced zunsemetinib into a Phase 2b trial for hidradenitis suppurativa in late 2025 while discontinuing less viable assets to focus on high-potential programs. These changes position Aclaris to accelerate development in immunology segments, targeting dermatology clinics, rheumatologists, and pulmonologists globally through partnerships and potential commercialization. No major acquisitions or name changes have occurred recently.[web:previous]
Company News
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Deutsche Bank AG Makes New Investment in Aclaris Therapeutics, Inc. $ACRS
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
3 Penny Stocks Under $5 Backed by Real Revenue Growth
3 Penny Stocks Under $5 Backed by Real Revenue Growth
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4%
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference